Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$65.14
+2.6%
$63.77
$43.70
$86.53
$2.02B-1.545,296 shs11,872 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$17.47
+0.7%
$15.87
$8.02
$18.87
$8.62B1.6210.68 million shs7.16 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$12.57
-0.2%
$11.55
$8.73
$13.08
$8.60B1.155.01 million shs9.30 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$38.95
-2.1%
$37.26
$29.17
$62.40
$7.43B1.122.05 million shs1.75 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+2.57%+0.98%-1.76%+9.15%+34.56%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.73%-5.46%+22.65%+25.24%+16.28%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.16%+5.28%+8.08%+11.93%+6.98%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-2.06%+1.62%+1.46%-5.21%-8.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$65.14
+2.6%
$63.77
$43.70
$86.53
$2.02B-1.545,296 shs11,872 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$17.47
+0.7%
$15.87
$8.02
$18.87
$8.62B1.6210.68 million shs7.16 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$12.57
-0.2%
$11.55
$8.73
$13.08
$8.60B1.155.01 million shs9.30 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$38.95
-2.1%
$37.26
$29.17
$62.40
$7.43B1.122.05 million shs1.75 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+2.57%+0.98%-1.76%+9.15%+34.56%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.73%-5.46%+22.65%+25.24%+16.28%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.16%+5.28%+8.08%+11.93%+6.98%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-2.06%+1.62%+1.46%-5.21%-8.16%
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$4.72 per shareN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.95$2.27 per share7.70$12.33 per share1.42
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M295.48N/AN/A$7.45 per share1.69
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M628.75N/AN/A$13.47 per share2.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8620.3119.623.229.68%7.04%3.45%11/6/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)

Latest BLTE, ROIV, ELAN, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.47-$0.50-$0.03-$0.50N/AN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
23.15
23.15
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
40.54
40.54
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.13
11.79
11.79

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1031.84 million27.61 millionNot Optionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860682.88 million609.13 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.93 million171.60 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$65.14 +1.63 (+2.57%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$65.88 +0.73 (+1.13%)
As of 09/4/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$17.46 +0.12 (+0.66%)
Closing price 09/4/2025 03:59 PM Eastern
Extended Trading
$17.57 +0.10 (+0.57%)
As of 09/4/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$12.57 -0.02 (-0.16%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$12.54 -0.03 (-0.24%)
As of 04:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$38.95 -0.82 (-2.06%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$38.95 0.00 (0.00%)
As of 09/4/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.